Results of the base-case cost-utility analysis, the analysis on complete cases and the different sensitivity analyses
| Costs | Difference in costs | QALYs | Difference in QALYs | |||||||||
| COBRA-light | COBRA | COBRA-light | COBRA | |||||||||
| Main findings | Mean k€ | (SEM) | Mean k€ | (SEM) | k€ | (95% CI) | Mean | (SEM) | Mean | (SEM) | Mean | (95% CI) |
| Base case* | 9.293 | (0.920) | 7.222 | (0.780) | 1.980 | (−0.347 to 4.390) | 0.68 | (0.02) | 0.69 | (0.02) | −0.01 | (−0.06 to 0.04) |
| Analyses on complete cases† | 9.886 | (8.866) | 6.864 | (1.072) | 3.022 | (−0.764 to 6.682) | 0.69 | (0.02) | 0.70 | (0.02) | −0.01 | (−0.08 to 0.06) |
| Sensitivity analyses | ||||||||||||
| 1. Base case with correction for baseline factors* | 9.293 | (0.920) | 7.222 | (0.780) | 1.836 | (−0.347 to 4.189) | 0.68 | (0.02) | 0.69 | (0.02) | −0.01 | (−0.06 to 0.04) |
| 2. Analysis on patients with four or more returned diaries (per-protocol imputation)‡ | 9.897 | (1.139) | 7.343 | (0.910) | 2.554 | (−0.567 to 5.676) | 0.69 | (0.02) | 0.70 | (0.02) | −0.01 | (−0.06 to 0.04) |
| 3. Base case with etanercept use according to protocol* | 11.493 | (8.313) | 8.499 | (6.805) | 2.925 | (0.564 to 5.335) | 0.68 | (0.02) | 0.69 | (0.02) | −0.006 | (−0.06 to 0.04) |
*COBRA-light: n=79 and COBRA: n=77.
†COBRA-light: n=37 and COBRA: n=40.
‡COBRA-light: n=61 and COBRA: n=63.
COBRA, COmbinatie therapie Bij Reumatoïde Artritis; QALY, quality-adjusted life-years.